Safinamide is currently under clinical development by Meiji in Japan. Under the agreement, Eisai will obtain exclusive rights to safinamide to market in Japan and to develop and
FIN-524 is a live biotherapeutic product in pre-clinical research. It is composed of cultured bacterial strains that have been linked to favorable clinical outcomes in studies of microbiota
The Phase 2a single-dose trial is being conducted in the United Kingdom. The primary objective of this double-blind, placebo-controlled study will evaluate the pharmacokinetic and pharmacodynamics profile and
The Company has retained Stifel, Nicolaus & Company, Incorporated to serve as its financial advisor in the process. Aviragen Therapeutics does not have a defined timeline for the
The approval marks the first targeted treatment approved for the patient population, who previously had few treatment options, in all 28 member states of the European Union (EU),
Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized.
The results were presented in an oral session (OR08-1) at ENDO 2017, the Endocrine Society's Annual Meeting in Orlando, Fla. In the study, postmenopausal women with low bone
DPI and MDI devices are the most common forms of drug delivery in non-hospitalized patients with COPD and are well-suited for the maintenance therapy of COPD patients. The
The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of
Agenus plans to close its Basel site and consolidate key functions to its Cambridge, UK and Lexington, MA facilities, and phase out approximately 50 positions across the organization.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.